These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 84457)

  • 41. The epidemiology of Pseudomonas aeruginosa and the development of a polyvalent vaccine.
    Pranter W; Staerk J; Zellner R; Zwisler O
    Prog Immunobiol Stand; 1971; 5():414-8. PubMed ID: 4633968
    [No Abstract]   [Full Text] [Related]  

  • 42. Active and passive immunization against Pseudomonas aeruginosa infection of burned patients.
    Roe EA; Jones RJ
    Burns Incl Therm Inj; 1983 Jul; 9(6):433-9. PubMed ID: 6412970
    [TBL] [Abstract][Full Text] [Related]  

  • 43. X-ray Irradiated Vaccine Confers protection against Pneumonia caused by Pseudomonas aeruginosa.
    Li Y; Wang Z; Liu X; Tang J; Peng B; Wei Y
    Sci Rep; 2016 Feb; 6():18823. PubMed ID: 26879055
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Testing the protective effectiveness of vaccines against infection with Pseudomonas aeruginosa in mink (Lutreola vison)].
    Dousek J; Sourek J; Dvorák R; Hartman V; Vejlupek O
    Vet Med (Praha); 1986 Nov; 31(11):695-704. PubMed ID: 3097914
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Protective properties of antigenic preparations of Pseudomonas aeruginosa].
    Grishina IA; Kolker II; Stanislavskiĭ ES; Zhvanetskaia MI; Palkina MI
    Zh Mikrobiol Epidemiol Immunobiol; 1980 Jun; (6):63-7. PubMed ID: 6778029
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pseudomonas aeruginosa: prevention better than cure?
    Mellor JA; Miler JJ
    Dev Biol Stand; 1979; 43():53-9. PubMed ID: 118071
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Antigenic complexes of Pseudomonas aeruginosa slime: their isolation and biological properties].
    Aleksandrov AD; Antsiferova NG; Zhmyrina TI; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1984 Jan; (1):14-9. PubMed ID: 6422680
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy.
    Lee NG; Jung SB; Ahn BY; Kim YH; Kim JJ; Kim DK; Kim IS; Yoon SM; Nam SW; Kim HS; Park WJ
    Vaccine; 2000 Mar; 18(18):1952-61. PubMed ID: 10699346
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Experimental studies on the protective efficacy of a Pseudomonas aeruginosa vaccine.
    Stanislavsky ES; Edvabnaya LS; Bandman OA; Boolk VF; Zhvanetskaya MI; Vargina AK
    Vaccine; 1989 Dec; 7(6):562-6. PubMed ID: 2514518
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of cell wall Pseudomonas aeruginosa vaccines for protection against experimental pneumonia.
    Pennington JE; Pier GB
    Rev Infect Dis; 1983; 5 Suppl 5():S852-7. PubMed ID: 6419311
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vaccines against Pseudomonas aeruginosa results and perspectives of investigations (survey).
    Joó I; Stanislavskii ES
    J Hyg Epidemiol Microbiol Immunol; 1982; 26(4):417-27. PubMed ID: 6819316
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protective efficacy of recombinant exotoxin A--flagellin fusion protein against Pseudomonas aeruginosa infection.
    Farajnia S; Peerayeh SN; Tanomand A; Majidi J; Goudarzi G; Naghili B; Rahbarnia L
    Can J Microbiol; 2015 Jan; 61(1):60-4. PubMed ID: 25496361
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Experimental basis for the combined use of tobramycin and immune preparations for treating acute Pseudomonas aeruginosa infections].
    Minukhin VV; Tsyganenko VIa
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Aug; (8):42-5. PubMed ID: 3094301
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A new polyvalent Pseudomonas vaccine.
    Miler JM; Spilsbury JF; Jones RJ; Roe EA; Lowbury EJ
    J Med Microbiol; 1977 Feb; 10(1):19-27. PubMed ID: 402473
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Protective artificial polysaccharide-protein antigens made from the O-specific polysaccharides of Pseudomonas aeruginosa bacteria of the immunotypes 1, 2 and 7].
    Kul'shin VA; Antsiferova NG; Moroz AF; Dmitriev BA
    Zh Mikrobiol Epidemiol Immunobiol; 1988 Nov; (11):69-71. PubMed ID: 2464262
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterisation of mouse monoclonal antibodies produced by immunisation with a single serotype component of a polyvalent Pseudomonas aeruginosa vaccine.
    Barclay GR; Yap PL; McClelland DB; Jones RJ; Roe EA; McCann MC; Micklem LR; James K
    J Med Microbiol; 1986 Feb; 21(1):87-90. PubMed ID: 3081727
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Cell-free Pseudomonas vaccine. II. Isolation and immunological properties of protective antigens of Pseudomonas aeruginosa].
    Stanislavskiĭ ES; Palkina NA; Bulk VF; Zhvanetskaia MI; Chekan LV
    Zh Mikrobiol Epidemiol Immunobiol; 1981; (8):37-40. PubMed ID: 6797158
    [No Abstract]   [Full Text] [Related]  

  • 58. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.
    von Specht BU; Domdey H; Schödel F; Blum B; Lücking C; Knapp B; Muth G; Hungerer KD; Bröker M
    Behring Inst Mitt; 1994 Dec; (95):85-96. PubMed ID: 7538752
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Immunoprophylaxis and immunotherapy of experimental Pseudomonas aeruginosa sepsis].
    Grishina IA; Terekhova RP; Marchuk AI
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Apr; (4):14-7. PubMed ID: 3087118
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent Pseudomonas vaccine.
    Jones RJ; Roe EA
    Br J Exp Pathol; 1975 Feb; 56(1):34-43. PubMed ID: 812544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.